JP2021529732A5 - - Google Patents
Info
- Publication number
- JP2021529732A5 JP2021529732A5 JP2020569956A JP2020569956A JP2021529732A5 JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5 JP 2020569956 A JP2020569956 A JP 2020569956A JP 2020569956 A JP2020569956 A JP 2020569956A JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- pharmaceutical composition
- composition according
- esketamine
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000939A JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690419P | 2018-06-27 | 2018-06-27 | |
| US62/690,419 | 2018-06-27 | ||
| US201862698323P | 2018-07-16 | 2018-07-16 | |
| US62/698,323 | 2018-07-16 | ||
| US201862741564P | 2018-10-05 | 2018-10-05 | |
| US62/741,564 | 2018-10-05 | ||
| US201862769264P | 2018-11-19 | 2018-11-19 | |
| US62/769,264 | 2018-11-19 | ||
| PCT/IB2019/055453 WO2020003195A1 (en) | 2018-06-27 | 2019-06-27 | Method of treating major depressive disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000939A Division JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529732A JP2021529732A (ja) | 2021-11-04 |
| JP2021529732A5 true JP2021529732A5 (cg-RX-API-DMAC7.html) | 2022-04-25 |
| JP7903800B2 JP7903800B2 (ja) | 2026-08-12 |
Family
ID=67909427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569956A Active JP7903800B2 (ja) | 2018-06-27 | 2019-06-27 | 大うつ病性障害の処置方法 |
| JP2024000939A Pending JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000939A Pending JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12036189B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3813807B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7903800B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102793535B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112188889A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019293515B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020023882A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3103440A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278759B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020012475A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020003195A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| WO2020075134A1 (en) | 2018-10-11 | 2020-04-16 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| WO2021137147A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー. | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| WO2004004693A1 (en) | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| CN105534936B (zh) | 2007-08-13 | 2020-07-31 | Ohemo 生命科学股份有限公司 | 抗滥用药物、使用方法和制备方法 |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US9468611B2 (en) | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| WO2015066172A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| EP3272338B1 (en) | 2014-04-17 | 2020-09-09 | Develco Pharma Schweiz AG | Oral dosage form of ketamine |
| EP3193853A1 (en) * | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| KR102604397B1 (ko) | 2014-11-04 | 2023-11-21 | 아카디아 파마슈티칼스 인코포레이티드 | 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법 |
| CA2970065A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20160332962A1 (en) * | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| WO2018079693A1 (ja) | 2016-10-27 | 2018-05-03 | 国立大学法人 千葉大学 | (s)-ノルケタミンおよびその塩の医薬品としての応用 |
| WO2018102488A1 (en) | 2016-11-30 | 2018-06-07 | Wolfson Philip E | Ketamine for the treatment of menstrually related symptoms |
| EP3641742B1 (en) | 2017-06-23 | 2026-03-25 | Ketabon GmbH | Hydroxynorketamine for the use in the treatment of depression |
| MX2020003546A (es) | 2017-10-10 | 2020-08-03 | Douglas Pharmaceuticals Ltd | Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| EP3923920A4 (en) | 2019-08-05 | 2022-11-23 | The Ketamine Research Foundation | KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
-
2019
- 2019-06-27 CA CA3103440A patent/CA3103440A1/en active Pending
- 2019-06-27 KR KR1020207036721A patent/KR102793535B1/ko active Active
- 2019-06-27 AU AU2019293515A patent/AU2019293515B2/en active Active
- 2019-06-27 WO PCT/IB2019/055453 patent/WO2020003195A1/en not_active Ceased
- 2019-06-27 IL IL278759A patent/IL278759B2/en unknown
- 2019-06-27 BR BR112020023882-1A patent/BR112020023882A2/pt unknown
- 2019-06-27 MX MX2020012475A patent/MX2020012475A/es unknown
- 2019-06-27 US US16/454,399 patent/US12036189B2/en active Active
- 2019-06-27 JP JP2020569956A patent/JP7903800B2/ja active Active
- 2019-06-27 EP EP19766075.6A patent/EP3813807B1/en active Active
- 2019-06-27 CN CN201980034997.3A patent/CN112188889A/zh active Pending
-
2024
- 2024-01-09 JP JP2024000939A patent/JP2024041855A/ja active Pending
- 2024-07-15 US US18/772,474 patent/US20240366530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| Montgomery et al. | Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability | |
| Cutler et al. | Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法 | |
| BR112020023882A2 (pt) | método para tratar transtorno depressivo maior | |
| Silva Filho et al. | Comment on “The importance of physical exercise during the coronavirus (COVID-19) pandemic” | |
| Lu et al. | Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| JP7034314B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| JP2022503771A5 (cg-RX-API-DMAC7.html) | ||
| Alavi et al. | Tranquilizer/Anxiolytics: Pregabalin | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| Bedard et al. | P0174-Mindfulness-based cognitive therapy reduces depression symptoms in people with a traumatic brain injury: Results from a pilot study | |
| Sharma et al. | POS-416 TREATING HCV INFECTION IN CHRONIC KIDNEY DISEASE IN DEVELOPING COUNTRY: OUR EXPERIENCE WITH LIMITED RESOURCES | |
| RU2000129499A (ru) | Лечение депрессии и фармацевтические препараты для этой цели | |
| Cooper et al. | Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP) | |
| Zhang et al. | A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis | |
| Downey | A New Way To Manage Depression Without Drugs | |
| Vieta | Why do we consider major depressive disorder to be a chronic illness? | |
| Palmer | Olanzapine/fluoxetine promising in hard-to-treat depression | |
| TW202539680A (zh) | 組合物在製備用於治療至少一種癌症的用途 | |
| Bauer et al. | P0173-Effect of once-daily extended release Quetiapine Fumarate (Quetiapine XR) as add-on to antidepressants in major depressive disorder (MDD) | |
| Glynn et al. | Combining herbs and drugs–at times a fractious marriage | |
| Bostankolu | Aripiprazole/fluoxetine/sertraline interaction |